In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, last year, the company brought in $3.2 billion in revenue, compared to more ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

The technology behind Moderna’s COVID-19 vaccine — mRNA packaged in lipid nanoparticles — has the potential to reduce disparities in global health and help fight future pandemics.

The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018 ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.